NewAmsterdam Pharma Co NV 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number:001-41562 NewAmsterdam Pharma Company N.V.(Exact Name of Registrant as Specified in its Charter) TheNetherlands( State or other jurisdiction ofincorporation or organization)Gooimeer 2-35NaardenTheNetherlands(Address of principal executive offices) Registrant’s telephone number, including area code:+31(0) 35 206 2971 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☐ Large accelerated filer☒Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 2, 2025, the registrant had112,270,677ordinary shares, nominal value€0.12 per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets7Condensed Consolidated Statements of Comprehensive Income (Loss)8Condensed Consolidated Statements of Shareholders' Equity (Deficit)9Condensed Consolidated Statements of Cash Flows10Notes to Unaudited Condensed Consolidated Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures26 PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements. Forward-looking statementsprovide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about theCompany’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Wordsor phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,”“ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or similar words or phrases, or the negatives ofthose words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that astatement is not forward-looking. Examples of forward-looking statements in this Quarterly Report include, but are not limited to,statements regarding the Company’s disclosure concerning its operations, cash flows, financial position and dividend policy. Forward-looking statements in this Quarterly Report and in any document incorporated by reference in this Quarterly Reportmay include, for example, statements about: •the potential liquidity and trading of the Company’s public securities;•the Company’s ability to raise additional capital in sufficient amounts or on terms acceptable to it;•the efficacy and safety of the Company’s product candidate, obicetrapib, as well as potential reimbursement andanticipated market size and market opportunity;•the Company’s dependence on the success of obicetrapib, including the obtaining of regulatory approval to marketobicetrapib;•the timing, progress and results of clinical trials for obicetrapib, including statements regarding the timing of initiation andcompletion of studies or trials and related preparatory work and the period during which results of trials wi